TEVA PHARMACEUTICAL FIN LLC's ticker is and the CUSIP is 88163VAE9. A total of 58 filers reported holding TEVA PHARMACEUTICAL FIN LLC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $17,487,000 | +2.5% | 17,400,000 | 0.0% | 0.20% | -21.8% |
| Q3 2020 | $17,060,000 | +0.2% | 17,400,000 | 0.0% | 0.26% | -23.2% |
| Q2 2020 | $17,024,000 | +5.1% | 17,400,000 | 0.0% | 0.34% | -21.8% |
| Q1 2020 | $16,191,000 | -2.4% | 17,400,000 | 0.0% | 0.44% | +41.6% |
| Q4 2019 | $16,581,000 | -1.0% | 17,400,000 | -5.4% | 0.31% | +2.3% |
| Q3 2019 | $16,752,000 | +73.5% | 18,400,000 | +75.2% | 0.30% | +69.1% |
| Q2 2019 | $9,653,000 | -0.8% | 10,500,000 | 0.0% | 0.18% | -10.1% |
| Q1 2019 | $9,733,000 | +78.8% | 10,500,000 | +75.0% | 0.20% | +46.7% |
| Q4 2018 | $5,445,000 | +44.8% | 6,000,000 | +50.0% | 0.14% | +154.7% |
| Q3 2018 | $3,761,000 | -42.3% | 4,000,000 | -42.9% | 0.05% | -41.1% |
| Q2 2018 | $6,523,000 | -19.6% | 7,000,000 | -23.9% | 0.09% | -25.6% |
| Q1 2018 | $8,109,000 | +14.9% | 9,200,000 | +15.0% | 0.12% | +39.1% |
| Q4 2017 | $7,060,000 | – | 8,000,000 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ZAZOVE ASSOCIATES LLC | 83,413,000 | $130,650,000 | 6.13% |
| AEGON USA Investment Management, LLC | 6,000,000 | $9,368,000 | 2.35% |
| MACKAY SHIELDS LLC | 24,370,000 | $38,152,000 | 2.07% |
| INCOME RESEARCH & MANAGEMENT | 4,374,000 | $6,829,000 | 1.11% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 20,000 | $20,347,000 | 0.99% |
| SHENKMAN CAPITAL MANAGEMENT INC | 5,269,000 | $8,264,000 | 0.82% |
| Mitsubishi UFJ Securities Holdings Co., Ltd. | 325,000 | $511,000 | 0.76% |
| PALISADE CAPITAL MANAGEMENT, LP | 9,299,000 | $14,598,000 | 0.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 14,543,000 | $23,021,000 | 0.35% |
| CSS LLC/IL | 3,750,000 | $5,893,000 | 0.35% |